GlobeNewswire: Abeona Therapeutics Inc. Contains the last 10 of 284 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:40:10ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/18/2847702/0/en/Abeona-Therapeutics-Reports-Full-Year-2023-Financial-Results-and-Announces-Completion-of-FDA-Inspections.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections2024-03-18T11:30:00Z<![CDATA[- FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study - - FDA completed Pre-License Inspection of Abeona’s Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study -]]>https://www.globenewswire.com/news-release/2024/03/05/2840322/0/en/Abeona-Therapeutics-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-03-05T12:30:00Z<![CDATA[CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/02/01/2822431/0/en/Abeona-Therapeutics-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-02-01T21:05:00Z<![CDATA[CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/02/01/2821881/0/en/Abeona-Therapeutics-Announces-Progress-Update-on-Pz-cel-Biologics-License-Application-BLA.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)2024-02-01T12:30:00Z<![CDATA[- On track for PDUFA target action date of May 25, 2024 -]]>https://www.globenewswire.com/news-release/2024/01/08/2805336/0/en/Abeona-Therapeutics-Announces-50-Million-Credit-Facility.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Announces $50 Million Credit Facility2024-01-08T12:30:00Z<![CDATA[CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities Fund, L.P. The credit agreement, which has a term of three and a half years, includes a first tranche of $20 million at closing, a second tranche of $10 million of committed capital, and an additional accordion option to upsize the credit facility by an additional $20 million upon satisfaction of certain terms and conditions.]]>https://www.globenewswire.com/news-release/2023/12/15/2796994/0/en/Abeona-Therapeutics-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-12-15T12:30:00Z<![CDATA[CLEVELAND, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2023/11/27/2786066/0/en/Abeona-Therapeutics-Announces-FDA-Accepts-and-Grants-Priority-Review-for-Pz-cel-Biologics-License-Application-BLA.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)2023-11-27T12:30:00Z<![CDATA[- PDUFA target action date is May 25, 2024 -]]>https://www.globenewswire.com/news-release/2023/11/13/2778937/0/en/Abeona-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Corporate-Developments.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments2023-11-13T12:30:00Z<![CDATA[Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023]]>https://www.globenewswire.com/news-release/2023/11/01/2771021/0/en/Abeona-Therapeutics-Announces-New-Employee-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-11-01T11:30:00Z<![CDATA[CLEVELAND, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2023/09/26/2749360/0/en/Abeona-Therapeutics-Submits-Biologics-License-Application-to-U-S-FDA-Seeking-Priority-Review-and-Approval-of-EB-101-for-the-Treatment-of-Patients-with-Recessive-Dystrophic-Epidermo.html?f=22&fvtc=4&fvtv=31139Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa2023-09-26T11:30:00Z<![CDATA[CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). As part of the submission, Abeona requested a Priority Review, which, if granted, would shorten the FDA’s review period to six months from the filing acceptance of the BLA, instead of 10 months under standard review.]]>